Remuzzi A, Malanchini B, Battaglia C, Bertani T, Remuzzi G
Mario Negri Institute for Pharmacological Research, Bergamo, Italy.
Exp Nephrol. 1996 Jan-Feb;4(1):19-25.
The mechanism by which angiotensin-converting enzyme (ACE) inhibitors prevent proteinuria and glomerulosclerosis in experimental nephropathies is not yet clear. Experimental evidence is available that the effect of ACE inhibitors on the glomerular function depends on the inhibition of angiotensin II generation, but it is possible that inhibition of the bradykinin breakdown also plays a relevant role. To establish the mediators of the effects of ACE inhibitors in glomerular injury, we compared the effects of the ACE inhibitor lisinopril with those of a specific angiotensin receptor (AT1) antagonist (ZD7155) on the renal function in male MWF/Ztm rats. After 4 months (end of the study), the untreated animals developed hypertension and proteinuria (160 +/- 10 mm Hg and 214 +/- 92 mg/24 h, respectively). In the lisinopril- and in the ZD7155-treated rats, a comparable systolic pressure control was achieved (121 +/- 12 and 118 +/- 14 mm Hg, respectively), and proteinuria was significantly prevented (averaging only 38 +/- 23 and 30 +/- 8 mg/24h, respectively) at the end of the study. The glomerular filtration rate was comparable in control and lisinopril-treated rats and significantly increased in ZD7155-treated rats. Both treatments significantly reduced the glomerular capillary pressure and significantly increased the ultrafiltration coefficient (Kf) as compared with untreated animals. In ZD7155-treated rats the Kf was also significantly higher than in untreated animals glomerular sclerosis and tubulointerstitital damage developed. Structural changes were absent in lisinopril- and ZD7155-treated animals. These results show that the antihypertensive and renal protective effects of ACE inhibitors are shared by the angiotensin receptor antagonist. Thus, angiotensin II is the likely mediator of proteinuria and glomerulosclerosis which develop spontaneously with age in this model.
血管紧张素转换酶(ACE)抑制剂预防实验性肾病中蛋白尿和肾小球硬化的机制尚不清楚。现有实验证据表明,ACE抑制剂对肾小球功能的影响取决于对血管紧张素II生成的抑制,但缓激肽降解的抑制也可能起相关作用。为了确定ACE抑制剂在肾小球损伤中的作用介质,我们比较了ACE抑制剂赖诺普利与特异性血管紧张素受体(AT1)拮抗剂(ZD7155)对雄性MWF/Ztm大鼠肾功能的影响。4个月后(研究结束时),未治疗的动物出现高血压和蛋白尿(分别为160±10 mmHg和214±92 mg/24 h)。在赖诺普利和ZD7155治疗的大鼠中,实现了相当的收缩压控制(分别为121±12和118±14 mmHg),并且在研究结束时蛋白尿得到了显著预防(分别平均仅为38±23和30±8 mg/24h)。对照组和赖诺普利治疗的大鼠肾小球滤过率相当,而ZD7155治疗的大鼠肾小球滤过率显著增加。与未治疗的动物相比,两种治疗均显著降低了肾小球毛细血管压力并显著增加了超滤系数(Kf)。在ZD7155治疗的大鼠中,Kf也显著高于未治疗的动物,出现了肾小球硬化和肾小管间质损伤。赖诺普利和ZD7155治疗的动物没有结构变化。这些结果表明,血管紧张素受体拮抗剂具有与ACE抑制剂相同的降压和肾脏保护作用。因此,血管紧张素II可能是该模型中随年龄自发出现的蛋白尿和肾小球硬化的介质。